Mobile

A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented adva...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-002241-39

A multicentre, double-blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who have not experienced disease progression or unacceptable toxicity during chemotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine if the administration of Tarceva after standard platinum based chemotherapy in the treatment of NSCLC results in improved Progression Free Survival (PFS) when compared to placebo. 1. In all patients. 2. In patients who are EGFR protein expression (IHC) positive.

Critère d'inclusion

  • Advanced (stage IIIB or IV) NSCLC previously treated with 4 cycles of a platinum-based chemotherapy

Liens